AJDRAJNR - American Journal of Neuroradiology

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deliganis, A. V.
Right arrow Articles by Maravilla, K. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deliganis, A. V.
Right arrow Articles by Maravilla, K. R.

American Journal of Neuroradiology, Vol 18, Issue 8 1401-1406, Copyright © 1997 by American Society of Neuroradiology


ARTICLES

Serial MR in gene therapy for recurrent glioblastoma: initial experience and work in progress

AV Deliganis, AB Baxter, MS Berger, SG Marcus and KR Maravilla
Department of Radiology, University of Washington School of Medicine, Seattle, USA.

PURPOSE: To describe the MR imaging findings in a pilot study evaluating gene therapy for treatment of patients with recurrent glioblastoma. METHODS: Serial MR examinations were evaluated retrospectively in patients treated with gene therapy that included a retroviral vector containing the herpes simplex virus thymidine kinase gene and intravenous ganciclovir. Images were obtained after tumor resection and after each cycle of treatment, at approximately 40-day intervals. The volume of enhancing tissue was measured on serial MR images. RESULTS: Eleven patients with recurrent glioblastoma were entered into the clinical trial of gene therapy and seven patients completed at least two cycles of treatment. Of these seven, three patients had an early (between 40 and 80 days) increase in the volume of enhancing tissue followed by a decrease or plateau in enhancing tissue volume. A fourth patient had a stable volume of enhancing tissue for 132 days. The remaining three patients had continuous increases in volume of enhancement on all subsequent MR examinations. CONCLUSION: Although animal data show striking tumor regression in response to similar gene therapy, only limited regression was observed among the seven patients we studied. The transient increases in enhancement seen in three of seven patients might reflect an inflammatory response to local injection of the viral vector.


This article has been cited by other articles:


Home page
NeurologyHome page
F.-W. Floeth, K. J. Langen, G. Reifenberger, and F. Weber
Tumor-free survival of 7 years after gene therapy for recurrent glioblastoma
Neurology, July 22, 2003; 61(2): 270 - 271.
[Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
U. Haberkorn and A. Altmann
Imaging Techniques for Gene Therapy: SPECT, PET, and MRI
Journal of Pharmacy Practice, October 1, 2001; 14(5): 383 - 396.
[Abstract] [PDF]


Home page
Am. J. Neuroradiol.Home page
F. W. Floeth, A. Aulich, K. J. Langen, K. J. Burger, W. J. Bock, and F. Weber
MR Imaging and Single-Photon Emission CT Findings after Gene Therapy for Human Glioblastoma
AJNR Am. J. Neuroradiol., September 1, 2001; 22(8): 1517 - 1527.
[Abstract] [Full Text] [PDF]